IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
about
The role of CD95 and CD95 ligand in cancerSystemic IL-12 administration alters hepatic dendritic cell stimulation capabilitiesIL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors.Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression.Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice.Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma.Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patientsVEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.Fas expression by tumor stroma is required for cancer eradication.Immunotherapy of cancer by IL-12-based cytokine combinationsAn NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivoCD8 engineered cytotoxic T cells reprogram melanoma tumor environment.Decoy receptor 3 is a prognostic factor in renal cell cancerAn effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cellsAging predisposes to acute inflammatory induced pathology after tumor immunotherapy.Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.Interleukins and cancer immunotherapy.Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27.TRUCKs: the fourth generation of CARs.High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response.Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice.IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer.DICE: A novel tumor surveillance mechanism-a new therapy for cancer?Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells.Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.Inhibition of interleukin-12 expression by alpha-thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses.Simian virus-40 infection inhibits DNA damage-induced enhancement of CD95 expression and function.Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).
P2860
Q26995847-8C7CFFE2-B3BB-4741-815A-08CD9CE38A6DQ28512535-2780DBB9-38D2-4FE9-83AE-BBF36A36D3FEQ33670036-02B47707-F417-434B-8BFA-E0A70743C614Q33738154-D48D1EF8-5BF6-42AC-8A65-A359C56FEC63Q33863928-847F969F-570C-4A45-B82D-CEDD9E6BFF1FQ34119602-5340579F-0499-427C-8C9C-50D7BF7BBA44Q34668901-F651BCE7-3EEB-4A91-9DE1-CAD71E67266FQ36057487-2F2EBFFE-BD0E-409F-B59F-FB88F835F535Q36371399-95301D0F-4261-40E4-A813-9CFFF38F364FQ36598412-290D51E2-469A-46B6-8A55-C22A1C62342EQ36724827-4AC48490-415F-4D01-A240-DE2A67FA396DQ36787587-3EA9E98B-DCE7-4796-B42A-7BE44426CFBBQ36821069-C1F820B4-7B21-4671-B2CE-0F1DD5DDE33EQ36897759-475B4895-F981-4D67-872E-37E8AF6B863CQ37189574-1569B99F-CF53-4D4D-AFEC-5A7CC4C8E4BDQ37246492-06B9A975-F703-4311-955D-5E1F09FE6F17Q37306957-93134827-C7A5-49F1-8BB4-6ACCDFF859F4Q37773302-0D3DB79E-0A80-4246-B8B7-C153323CF918Q37795583-EE2CAF44-4997-43C4-BD8B-12F5657817B3Q38488557-3214FD4D-981D-460E-877A-9CAA4D144456Q39351465-61B6B5EA-847E-448B-BDD1-7DFBFCE7000EQ39491926-8D3E9B03-BEBF-4C71-A2A5-A19BF2A664C2Q39799240-7CA24A8A-67FB-4138-AC13-A7DBB419B798Q40164065-05A465D6-13CF-466D-A831-6D2B6C759B60Q40348649-001DAD91-D1F8-4177-BE0C-0FABADA9371CQ40370693-A1C5B816-7A51-43ED-B5EC-F320CA61A079Q40464867-1A229913-4210-4AE2-8BEE-B19794CAFD5CQ40628176-8B6A2325-F4C3-44A6-AA11-0E1C2CD8B465Q40965523-8A8BBF8D-98CF-4D86-95B4-F3938C2706CDQ43252637-650006FB-B6FC-440E-8D2B-E366F28C5665Q43263193-1C78E51E-B339-4F4D-94C5-A01CEE3FBA46Q45734015-A5E9143F-F2A4-4CE5-9262-6EDA684A57BBQ45870945-FAEBC19D-6E83-4410-A38A-FA6D48AC8C4AQ49243761-44071D9C-6783-43A9-9184-9183C8B1E7D5
P2860
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
IFN-gamma and Fas/FasL are req ...... s of IL-12/pulse IL-2 therapy.
@ast
IFN-gamma and Fas/FasL are req ...... s of IL-12/pulse IL-2 therapy.
@en
type
label
IFN-gamma and Fas/FasL are req ...... s of IL-12/pulse IL-2 therapy.
@ast
IFN-gamma and Fas/FasL are req ...... s of IL-12/pulse IL-2 therapy.
@en
prefLabel
IFN-gamma and Fas/FasL are req ...... s of IL-12/pulse IL-2 therapy.
@ast
IFN-gamma and Fas/FasL are req ...... s of IL-12/pulse IL-2 therapy.
@en
P2093
P2860
P356
P1476
IFN-gamma and Fas/FasL are req ...... s of IL-12/pulse IL-2 therapy.
@en
P2093
J M Wigginton
J Subleski
K L Komschlies
K Nagashima
L Geiselhart
R H Wiltrout
T A Wiltrout
P2860
P356
10.1172/JCI200110128
P407
P577
2001-07-01T00:00:00Z